TY - JOUR
T1 - Risk of Ovarian Cancer and the NF-κB Pathway
T2 - Genetic Association with IL1A and TNFSF10
AU - Charbonneau, Bridget
AU - Block, Matthew S
AU - Bamlet, William R
AU - Vierkant, Robert A
AU - Kalli, Kimberly R
AU - Fogarty, Zachary
AU - Rider, David N
AU - Sellers, Thomas A
AU - Tworoger, Shelley S
AU - Poole, Elizabeth
AU - Risch, Harvey A
AU - Salvesen, Helga B
AU - Kiemeney, Lambertus A
AU - Baglietto, Laura
AU - Giles, Graham G
AU - Severi, Gianluca
AU - Trabert, Britton
AU - Wentzensen, Nicolas
AU - Chenevix-Trench, Georgia
AU - Whittemore, Alice S
AU - Sieh, Weiva
AU - Chang-Claude, Jenny
AU - Bandera, Elisa V
AU - Orlow, Irene
AU - Terry, Kathryn
AU - Goodman, Marc T
AU - Thompson, Pamela J
AU - Cook, Linda S
AU - Rossing, Mary Anne
AU - Ness, Roberta B
AU - Narod, Steven A
AU - Kupryjanczyk, Jolanta
AU - Lu, Karen
AU - Butzow, Ralf
AU - Dörk, Thilo
AU - Pejovic, Tanja
AU - Campbell, Ian
AU - Le, Nhu D
AU - Bunker, Clareann H
AU - Bogdanova, Natalia
AU - Runnebaum, Ingo B
AU - Eccles, Diana
AU - Paul, James
AU - Wu, Anna H
AU - Gayther, Simon A
AU - Hogdall, Estrid
AU - Heitz, Florian
AU - Hogdall, Claus K
AU - Kjaer, Susanne Kruger
AU - Jensen, Allan
AU - for AOCS/ACS group
PY - 2014/2/1
Y1 - 2014/2/1
N2 - A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1a (IL1A) is both regulated by and able to activate NF-kB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-kB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76-0.93; P < 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75-0.95; P < 0.006). Considering a multiple-testing-corrected significance threshold of P < 2.5 ± 10-5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79-0.91; P < 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted.
AB - A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1a (IL1A) is both regulated by and able to activate NF-kB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-kB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76-0.93; P < 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75-0.95; P < 0.006). Considering a multiple-testing-corrected significance threshold of P < 2.5 ± 10-5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79-0.91; P < 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted.
KW - Case-Control Studies
KW - Female
KW - Genetic Association Studies
KW - Humans
KW - Interleukin-1alpha
KW - NF-kappa B
KW - Ovarian Neoplasms
KW - Polymorphism, Single Nucleotide
KW - Risk
KW - Signal Transduction
KW - TNF-Related Apoptosis-Inducing Ligand
U2 - 10.1158/0008-5472.CAN-13-1051
DO - 10.1158/0008-5472.CAN-13-1051
M3 - Journal article
C2 - 24272484
SN - 0008-5472
VL - 74
SP - 852
EP - 861
JO - Cancer Research
JF - Cancer Research
IS - 3
ER -